Science 37®’s Community Provider Network Grows Sixfold, Reaching Nearly 28 Million Patients
February 17 2022 - 7:55AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™ bolstered its centralized network of community
providers by six times during the past year, contracting with more
than 800 healthcare organizations and gaining access to nearly 28
million patients worldwide.
Currently, less than three percent of physicians participate as
clinical trial investigators, primarily due to infrastructure
burdens that often serve as a deterrent – preventing more than 97
percent of providers from contributing to research1. By expanding
its network of community providers, Science 37 enables
physicians-providers to present clinical research as a care option
to their patients, without having to add expensive clinical
research infrastructure.
“Continuing to expand our network of community providers
delivers against our mission: to accelerate research by enabling
universal access to patients and providers, anywhere,” said Darcy
Forman, Chief Delivery Officer of Science 37. “Our community
provider network helps speed patient enrollment, which has been
proven to enroll up to 15 times faster than the traditional model.
It also dramatically extends our investigator capacity and enables
us to take on more complex study designs across most therapeutic
areas.”
Science 37-Certified™ community providers have the opportunity
to present their patients with studies that are managed by Science
37 telemedicine investigators, or they may choose to become an
investigator with Science 37 and utilize the Science 37’s Agile
Clinical Trial Operating System. Community providers may also
become a preferred destination for patients to receive procedures
that may be required to be performed in a clinical setting.
“The Science 37 Operating System, including its centralized
networks, standardized processes and unifying technology platform,
enables the entire trial to be conducted by a common set of people,
processes and technology,” Ms. Forman continued. “We believe this
enables Science 37 to not only accelerate enrollment, but also to
create greater compliance to the protocol and the highest-quality
data.”
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to enable universal access to clinical
research—making it easier for patients and providers to participate
from anywhere and helping to accelerate the development of
treatments that impact patient lives. As a pioneer of decentralized
clinical trials, the Science 37 Agile Clinical Trial Operating
System (OS) supports today’s more agile clinical research designs
with its full stack, end-to-end technology platform and centralized
networks of patient communities, telemedicine investigators, mobile
nurses, remote coordinators, provider communities, and data and
devices. Configurable to enable almost any study type, the Science
37 OS enables up to 15x faster enrollment, 28% better retention and
3x more diverse patient population with industry-leading workflow
orchestration, evidence generation and data harmonization. For more
information, visit https://www.science37.com.
MEDIA INQUIRIES
Margie KoomanScience 37Phone: (984)
377-3737Email: pr@science37.com
INVESTOR RELATIONS:Caroline PaulGilmartin
GroupInvestors@science37.com
1The Decentralized Clinical Trial Landscape, January 21, 2022,
Baird Equity Research
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024